| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DNA polymerase zeta catalytic subunit; DPOLZ; DPOZ; EC 2.7.7.7; POLZ |
| Entrez GeneID | 5980; |
| WB Predicted band size | 352kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human DNA Polymerase ζ. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于DNA Polymerase ζ(Pol ζ)抗体的参考文献摘要：
1. **文献名称**: *"Characterization of a human antibody targeting DNA Polymerase ζ catalytic subunit REV3L"*
**作者**: Smith J. et al.
**摘要**: 该文献报道了一种针对REV3L(Pol ζ催化亚基)的单克隆抗体的开发与验证，通过免疫沉淀和免疫印迹技术证实了其在检测内源性及外源性REV3L蛋白中的高特异性，并用于研究Pol ζ在癌细胞DNA损伤修复中的作用。
2. **文献名称**: *"REV7 and REV3L interaction in translesion synthesis: Insights from antibody-based inhibition studies"*
**作者**: Garcia-Rodriguez F.J. et al.
**摘要**: 研究利用针对REV7(Pol ζ辅助亚基)和REV3L的多克隆抗体，通过共免疫沉淀和功能抑制实验，揭示了Pol ζ亚基互作对跨损伤合成(TLS)的关键调控机制，并证明其与化疗耐药性相关。
3. **文献名称**: *"DNA Polymerase ζ deficiency enhances genomic instability in human cancers"*
**作者**: Wang L. et al.
**摘要**: 该研究使用抗REV3L抗体对多种癌症组织样本进行免疫组化分析，发现Pol ζ低表达与染色体不稳定性增加及患者预后不良显著相关，提示其作为癌症生物标志物的潜力。
4. **文献名称**: *"A novel monoclonal antibody against DNA Polymerase ζ for detecting somatic hypermutation in B-cells"*
**作者**: Tanaka K. et al.
**摘要**: 文献描述了一种新型抗Pol ζ单克隆抗体的开发，结合流式细胞术和免疫荧光技术，证实Pol ζ在B细胞体细胞超突变中的活跃表达，为免疫系统DNA损伤应答研究提供了工具。
(注：以上文献为示例性内容，实际文献需通过数据库检索获取。)
DNA polymerase ζ (Pol ζ) is a specialized enzyme in the DNA damage tolerance pathway, primarily involved in translesion DNA synthesis (TLS) to bypass replication-blocking lesions. Composed of the catalytic subunit REV3L and accessory subunits REV7 (MAD2L2), Pol ζ plays a critical role in maintaining genomic stability by enabling DNA replication past bulky DNA adducts or crosslinks that stall replicative polymerases. Unlike most TLS polymerases, Pol ζ exhibits low fidelity but extended synthesis capacity, making it essential for error-prone repair mechanisms linked to mutagenesis and cancer development.
Antibodies targeting Pol ζ (particularly REV3L or REV7) are vital tools for studying its expression, localization, and functional interactions. These antibodies enable researchers to investigate Pol ζ's role in cancer biology, chemotherapy resistance (e.g., cisplatin resistance), and somatic hypermutation in adaptive immunity. Immunoblotting, immunofluorescence, and immunohistochemistry applications help quantify Pol ζ levels in tumors, where its overexpression often correlates with poor prognosis. Additionally, Pol ζ-specific antibodies are used to explore its partnership with other TLS factors (e.g., Pol η) and regulatory mechanisms involving ubiquitination or PCNA modifications. Recent studies also employ these reagents to assess Pol ζ's involvement in mitochondrial DNA maintenance and its potential as a therapeutic target. Validation via knockout models or functional assays ensures antibody specificity, given structural similarities among DNA polymerases.
×
